ClinicalTrials.gg
CompletedNCT06299826LUMINARAUpdated Jul 8, 2026

A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure

A Phase 2 interventional study of AZD5462 and Placebo in Chronic Heart Failure, sponsored by AstraZeneca. Completed at 57 sites in 10 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
375
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Heart Failure by AstraZeneca — 6 open to participants now, 8 under way, 3 of them phase 3. Heart Failure · AstraZeneca.

Enrollment
13th of 39
375 · median 160
Started
2024
with 6 others
Phase 2
8 of 64
none open now
Registered
54th of 64
by date

Among the 64 studies in Heart Failure by AstraZeneca, this one is the 13th largest by enrollment of the 39 interventional ones that give a count, is one of 7 that started in 2024, is one of 8 in phase 2, and was the 54th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

6 of the 64 studies in Heart Failure by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Heart Failure by AstraZeneca, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the effect of AZD5462 on cardiac function in participants with chronic heart failure (HF).

Read the detailed description

This is a Phase IIb randomized, double-blind, placebo-controlled, multi-center, dose-ranging study to evaluate the efficacy, safety, and pharmacokinetic (PK) of AZD5462 on top of standard of care in 2 cohorts of participants with HF: Cohort A, and Cohort B.

The study will include 3 periods and approximately 12 study visits:

  • Screening period of up to 4 weeks (at least 1 study visit)
  • Treatment period of 24 weeks (8 study visits)
  • Follow-up period of 4 weeks (3 study visits)

Eligible participants in each cohort will be randomized equally 1:1:1:1 to receive a once daily dose (OD) of 3 dose levels (low, medium, or high) oral dose of AZD5462 tablets or placebo.

03

Conditions studied

  • Chronic Heart Failure

Browse trials for

Keywords

  • Relaxin Family Peptide Receptor 1 (RXFP1) agonist
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a pre-existing diagnosis of HF FC II to IV.
  • Participants must be on stable HF standard of care medication for at least 4 weeks prior to consent and during the Screening period.
  • Minimum (BMI) of 18 kilograms per meter square (kg/m\^2) at Screening.
  • For female participants, the participant must not be pregnant or lactating and must be of non-.
  • All male participants should refrain from fathering a child or donating sperm until 3 months after the final study Follow-up Visit. Non-sterilised male participants should avoid fathering a child either by true abstinence or use of a condom for all sexual intercourse with a female partner of childbearing potential from the first dose until 3 months after the final Follow-up Visit.

Exclusion criteria

Exclusion Criteria:

  • Historical or current evidence of a disease or disorder including, but not limited to:

    1. Myocardial infarction, stroke, , coronary artery bypass grafting, or percutaneous coronary intervention within 12 weeks prior to consent or transcatheter structural heart interventions or cardiac valve surgery within 6 months prior to consent.
    2. Sarcoidosis, restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, or hypertrophic (obstructive) cardiomyopathy.
    3. History of untreated clinically significant valve disease or a Screening confirmation of severe aortic stenosis, severe mitral stenosis, moderate or severe aortic insufficiency or severe mitral insufficiency.
    4. Amyloidosis, Fabry disease, or haemochromatosis.
    5. Pericardial disease (i.e., visually significant white pericardium on echocardiogram).
    6. Known coagulation disorders.
    7. Current diagnosis of active hepatitis.
    8. Severe pulmonary disease that is not expected to improve over time, as assessed by the investigator.
    9. Decompensated HF or any cardiopulmonary hospitalisation, except planned hospitalisation without worsening of cardiac or pulmonary functions, within 4 weeks prior to consent or during the Screening period.
    10. History of active within 2 years, except for fully excised or treated basal cell carcinoma, or ≤ 2 squamous cell carcinomas of the skin and participants who are under investigation for breast or cervical cancer, including participants with a pap smear of grade ≥ 3.
  • History of to AZD5462 or any component of AZD5462 drug product.
  • Known history of drug or alcohol abuse within 24 months of Screening.
  • Congenital long syndrome or history of QT prolongation associated with other medications that required discontinuation of that medication.
  • Cardiac ventricular arrhythmia that requires treatment.
  • History of or anticipated heart transplant.
  • Current or planned cardiac resynchronization therapy/bi-ventricular pacemaker or mechanical assist device implantation.
  • Any planned highly invasive cardiovascular procedure (eg, coronary revascularisation, ablation of atrial fibrillation/flutter etc).
  • Positive antibody, or virus surface antigen at Screening. Participants with positive hepatitis B virus core antibody can be included in the study as long as hepatitis B virus surface antigen is negative, and there are no other signs of an active hepatitis B.
  • Known to have historically tested positive for .
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
375 participants (actual)

Study arms

  • Experimental
    Cohort A & B: AZD5462 low dose

    Participants will receive low dose of AZD5462 as OD tablets for 24 weeks.

    Drug: AZD5462

  • Experimental
    Cohort A & B: AZD5462 medium dose

    Participants will receive medium dose of AZD5462 as OD tablets for 24 weeks.

    Drug: AZD5462

  • Experimental
    Cohort A & B: AZD5462 high dose

    Participants will receive high dose of AZD5462 as OD tablets for 24 weeks.

    Drug: AZD5462

  • Experimental
    Cohort A & B: Placebo

    Participants will receive matching placebo OD tablets for 24 weeks.

    Drug: Placebo

Interventions

  • Participants will receive low, medium \& high doses of film-coated tablets of AZD5462 OD orally.

  • DrugPlacebo

    Participants will receive matching doses of film-coated tablets of Placebo OD orally.

06

What researchers measure

Primary outcomes

  1. Cohort A and B: Change from Baseline in Echocardiography Parameters

    To evaluate the effect of AZD5462 after treatment in participants with HF.

    Time frame: From Baseline to Week 25

Secondary outcomes

  1. Cohort A and B: Change from Baseline in Echocardiography Parameters

    To evaluate the effect and dose response of AZD5462 and effect on echocardiographic markers related to structural, systolic and diastolic function after treatment in participants with HF.

    Time frame: From Baseline to Week 13 and Week 25

  2. Cohorts A and B: Change from Baseline in Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ-OSS)

    To evaluate the effect of AZD5462 on HF health status in participants with HF. The KCCQ is a validated questionnaire developed for patients with congestive HF. It is a 23-item, self-administered health status measure that quantifies physical limitations, symptoms, social interference, self-efficacy, and quality of life. Results for each domain are summarized and transformed to a score of 0 to 100 with higher scores indicating better health status.

    Time frame: From Baseline to Weeks 3, 5, 13, and 25

  3. Cohorts A and B: Change from Baseline in New York Heart Association Functional Class (NYHA FC)

    To evaluate the effect of AZD5462 on HF health status in participants with HF. The NYHA Functional Classification is a system to measure the severity of symptoms of heart failure. It places patients in four categories based on limitations of physical activity, from Class I with no limitation, progressing to Class IV with severe limitations.

    Time frame: Baseline and Week 25

  4. Cohorts A and B: Change from Baseline in cardiac biomarkers

    To evaluate the effect of AZD5462 on biomarkers of cardiac function in treatment participants with HF.

    Time frame: From Baseline to Weeks 5, 13, and 25

  5. Cohorts A and B : Plasma Concentration of AZD5462

    To evaluate the PK of AZD5462 after repeat OD oral dosing in participants with HF.

    Time frame: Day 15 (Week 3), Day 29 (Week 5) and 85 (Week 13)

  6. Cohorts A and B: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    To evaluate the safety and tolerability of AZD5462 as compared to placebo in participants with HF.

    Time frame: From Baseline to Week 29 (Day 197)

07

Study locations

57 sites
  • Research Site
    Alexander City, Alabama 35010, United States
  • Research Site
    Northridge, California 91325, United States
  • Research Site
    Torrance, California 90502, United States
  • Research Site
    Vista, California 92081, United States
  • Research Site
    Miami, Florida 33133, United States
  • Research Site
    Miami Beach, Florida 33140, United States
  • Research Site
    Richmond, Indiana 47374, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Buffalo, New York 14215, United States
  • Research Site
    Rosedale, New York 11422, United States
  • Research Site
    Chapel Hill, North Carolina 27599, United States
  • Research Site
    Philadelphia, Pennsylvania 19107, United States
  • Research Site
    Knoxville, Tennessee 37916, United States
  • Research Site
    Manassas, Virginia 20109, United States
  • Research Site
    Pleven, 5800, Bulgaria
  • Research Site
    Pleven, 5803, Bulgaria
  • Research Site
    Sofia, 1309, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Sofia, 1527, Bulgaria
  • Research Site
    Brno, 625 00, Czechia
  • Research Site
    Jaroměř, 55101, Czechia
  • Research Site
    Liberec, 460 01, Czechia
  • Research Site
    Louny, 440 01, Czechia
  • Research Site
    Pilsen, 301 00, Czechia
  • Research Site
    Aalborg, 9000, Denmark
  • Research Site
    Herning, 7400, Denmark
  • Research Site
    Balatonfüred, 8230, Hungary
  • Research Site
    Kistarcsa, 2143, Hungary
  • Research Site
    Nyíregyháza, 4400, Hungary
  • Research Site
    Székesfehérvár, 8000, Hungary
  • Research Site
    Kochi, 682018, India
  • Research Site
    Kolkata, 700020, India
  • Research Site
    Surat, 395001, India
  • Research Site
    Vadodara, 390022, India
  • Research Site
    Fukui-shi, 910-8526, Japan
  • Research Site
    Higashiibaraki-gun, 311-3193, Japan
  • Research Site
    Higashiohmi-shi, 527-8505, Japan
  • Research Site
    Kitakyushu, 802-8555, Japan
  • Research Site
    Kobe, 654-0155, Japan
  • Research Site
    Kumamoto, 861-4193, Japan
  • Research Site
    Miyazaki, 880-0834, Japan
  • Research Site
    Morioka, 020-0066, Japan
  • Research Site
    Naha, 902-8511, Japan
  • Research Site
    Ōmihachiman, 523-0082, Japan
  • Research Site
    Shūnan, 745-8522, Japan
  • Research Site
    Breda, 4818 CK, Netherlands
  • Research Site
    Deventer, 7416 SE, Netherlands
  • Research Site
    Enschede, 7512 KZ, Netherlands
  • Research Site
    Krakow, 30-082, Poland
  • Research Site
    Krakow, 31-271, Poland
  • Research Site
    Lodz, 93-513, Poland
  • Research Site
    Warsaw, 01-249, Poland
  • Research Site
    Wroclaw, 50-556, Poland
  • Research Site
    Wroclaw, 53-114, Poland
  • Research Site
    Bratislava, 813 69, Slovakia
  • Research Site
    Bratislava, 821 07, Slovakia
  • Research Site
    Košice, 044 24, Slovakia
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environmentVivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Feb 2026, 20 months.

Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 20 months is close to that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2024
First posted
Mar 8, 2024
StartActual
Jun 4, 2024
Primary completionActual
Feb 10, 2026
CompletionActual
Feb 10, 2026
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06299826
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 8, 2024
Start date
Jun 4, 2024
Primary completion
Feb 10, 2026
Completion
Feb 10, 2026
Last update
Jul 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pexerelgon

Start the discussion